Yanping Hu

4.8k citations
117 papers · 1.7k · 1 hit paper · h-index 22

Impact in

  • Oncology top 5%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • HER2/EGFR in Cancer Research
    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research

Papers in

    • Lung Cancer Research Studies 15
    • Cancer Immunotherapy and Biomarkers 11
    • Peptidase Inhibition and Analysis 8
    • Colorectal Cancer Treatments and Studies 6
    • Drug Transport and Resistance Mechanisms 5

Yanping Hu

105 papers receiving 1.7k citations

Hit Papers

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer 2021 · 246 citations
2460+1+3Years since publication50100150200

Peers

Yanping Hu
Comparison fields: 5 of 151
  • Oncology 734
  • Cancer Research 334
  • Pulmonary and Respiratory Medicine 441
  • Molecular Biology 750
  • Biomaterials 86
Replace C.O. Granai with:
C.O. Granai United States
Shen Yao China
Feng Lin China
Sang‐Hee Cho South Korea
Ziwen Liu China
Myoung Hee Kang South Korea
Hong Qiu China
Tao Lin China
Chaoyang Sun China
Junji Matsuoka Japan
Yanping Hu relative to C.O. Granai United States C.O. Granai's profile →
Citations per field
00.5×5.4×
C.O. Granai · 1×
Citations per year

Countries citing papers authored by Yanping Hu

Since Specialization
Citations

This map shows the geographic impact of Yanping Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanping Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanping Hu more than expected).

Fields of papers citing papers by Yanping Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanping Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanping Hu. The network helps show where Yanping Hu may publish in the future.

Co-authors

The 25 scholars most cited alongside Yanping Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yanping Hu Line = papers co-authored together Yanping Hu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 117 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
Hit paper breakdown →
2021246
2
Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.
2003181
3 2020136
4 201869
5 201960
6
Tumor chemosensitization strategies based on apoptosis manipulations.
200345
7 200643
8 202041
9 202330
10 201730
11 201630
12 199629
13 202229
14 199527
15 201926
16 200423
17 201523
18 202423
19 202022
20 199622

About Yanping Hu

Yanping Hu is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Epidemiology, having authored 117 papers that have together received 1.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (15 papers), Cancer Immunotherapy and Biomarkers (11 papers), Peptidase Inhibition and Analysis (8 papers), Lung Cancer Diagnosis and Treatment (8 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer-related molecular mechanisms research (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). The work is most often cited by research in Oncology (734 citations), Cancer Research (334 citations), Pulmonary and Respiratory Medicine (441 citations), Molecular Biology (750 citations) and Biomaterials (86 citations). Yanping Hu has collaborated with scholars based in China, Canada and United States. Frequent co-authors include Lawrence D. Mayer, Jacques Robert, Robert G. Korneluk, Jon P. Durkin, Stephen Baird, Eric C. LaCasse, Jun Zhao, Huimin Wang, Yanli Li and Jennifer A. Shabbits. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Frontiers in Immunology and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact